Comment on “Identifying the minimum number of retrieved lymph nodes in node-negative duodenal adenocarcinoma: a retrospective analysis of the real-world data and SEER database”

To the Editor, Jiang et al[1] address a pragmatic but unresolved question in duodenal adenocarcinoma (DA): what minimum number of retrieved lymph nodes (rLNs) is needed to reduce understaging and better inform postoperative management. Using a real-world institutional cohort and a population-based Surveillance, Epidemiology and End Results (SEER) cohort (n = 1045), they propose rLN targets derived from multiple cutpoint approaches, translating them into actionable benchmarks of ≥13 rLNs for node-negative (N0) and ≥16 rLNs for N1 disease[1]. This commentary was prepared in accordance with the Transparency in the Reporting of Artificial Intelligence (TITAN) 2025 guideline to ensure transparent and responsible reporting[2]. This work is clinically relevant because lymph node evaluation is a well-established determinant of stage accuracy and survival in small bowel adenocarcinoma (SBA), and guideline-based risk stratification often incorporates “few nodes examined” as a high-risk feature[3]. Prior large database studies have suggested lower adequacy thresholds, for example, a minimum of five nodes for duodenal tumors to optimize staging in SBA – highlighting persistent uncertainty and site-specific variation[4]. Importantly, Ecker et al[5] showed in a matched NCDB cohort that, among node-negative DA, increasing LN assessment correlated with better survival, with the largest actuarial survival separation observed around ≥15 nodes, supporting a stage-migration interpretation. Against this background, Jiang et al[1] provide contemporary dual-cohort evidence that the “adequate node count” for DA may be higher than earlier SBA-wide estimates, particularly when modern pathological processing and standardized lymphadenectomy are achievable. A particularly insightful signal in the current study is that outcomes in N0-limited patients approximate those in N1-adequate patients, consistent with occult nodal disease being missed when nodal yield is low[1]. This concept aligns with broader SBA literature showing that the number of nodes evaluated (and nodal ratio metrics) meaningfully stratify prognosis after curative resection[4,6]. The authors’ exploratory finding that T4N0-limited patients may benefit from chemoradiotherapy, whereas T4N0-adequate patients do not, further underscores how nodal yield can modify confidence in “true” node negativity and influence adjuvant discussions[1]. Several cautions remain before adopting these thresholds as universal quality metrics. Cutpoint optimization can be sample-dependent, and rLN count reflects not only surgical extent but also specimen handling and pathological diligence. In addition, registry datasets lack granular variables (e.g. lymphovascular invasion, exact adjuvant regimens), limiting causal interpretation[1,5]. Nonetheless, the convergence of institutional and SEER findings strengthens the case that low nodal yield is not a benign technical detail in DA. Overall, Jiang et al. offer a useful benchmark – particularly ≥13 nodes for N0 DA – to inform operative planning, pathology protocols, and audit[1]. Prospective, multi-institutional validation with standardized lymphadenectomy templates and specimen-processing pathways is now needed to determine whether these nodal targets should be formalized in DA-specific guidance.